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Introduction {#sec001}
============

The spread of pathogens that have developed antimicrobial resistance (AMR), and the shortage of new antibiotics are critical issues in health care. Alternatives to traditional bacteriostatic and bactericidal agents have been proposed, such as reagents targeting bacterial proteins responsible for pathogenicity and/or drug resistance, including antitoxin agents and extended-spectrum β-lactamase (ESBL) inhibitors, respectively \[[@pone.0232461.ref001]--[@pone.0232461.ref002]\]. Such reagents, which assist therapies by using traditional drugs to treat infections, are associated with low rates of resistance, presumably because they do not affect bacterial growth.

Drug resistance is characterized as the inherited ability of bacteria to grow in a concentration of a drug that would otherwise prevent growth, and it is typically acquired by genetic modifications. In addition to drug resistance, drug tolerance of bacteria is recently re-considered as a potential critical issue. Drug tolerance is defined as a transient ability of bacteria to survive under bactericidal antibiotic treatments without having acquired a resistance phenotype, therefore, it is associated with the failure of antimicrobial chemotherapy \[[@pone.0232461.ref003]--[@pone.0232461.ref004]\].

Bacteria use particular signaling molecules, such as autoinducers, when they contact other bacteria, then alter the expression profile of subsets of genes \[[@pone.0232461.ref005]\]. In most of bacterial species, the communication mediated by these signaling compounds is closely associated with drug resistance, drug tolerance and pathogenicity, making them candidate targets for the treatment of refractory infectious diseases caused by pathogens resistant to commonly used antibiotics \[[@pone.0232461.ref006]\].

Bacterial signaling molecules have been the subject of extensive studies, particularly in pathogens. Many species of gram-negative bacteria use acyl-homoserine lactones and a derivative of 4,5-dihydroxy-2,3-pentanedione (DPD) termed autoinducer-2 \[[@pone.0232461.ref007]--[@pone.0232461.ref008]\]. As an exception, *Escherichia coli* strains do not produce acyl-homoserine lactones, but they produce autoinducer-2. In addition to autoinducer-2, *E*. *coli* also utilizes indole \[[@pone.0232461.ref009]\]. Tryptophanase (TnaA) is an enzyme that catalyzes a reaction from tryptophan into pyruvate, then indole is generated as a by-product.

Indole controls diverse cellular functions of bacteria including drug resistance, drug tolerance, biofilm formation and virulence as a signal molecule \[[@pone.0232461.ref010]--[@pone.0232461.ref012]\]. Previously, we found that indole increases expression of genes that encode proteins for drug efflux pumps and the type III secretion system, which contribute to drug tolerance and pathogenicity in host epithelial cells, respectively, in species, such as the food-borne pathogen enterohaemorrhagic *E*. *coli* (EHEC) \[[@pone.0232461.ref013]--[@pone.0232461.ref014]\]. On the other hand, indole decreases expression of *glpT*, which encodes the uptake transporter of fosfomycin with glycerol-3-phospate, leading to increased tolerance to fosfomycin \[[@pone.0232461.ref015]\].

In human host, indole is produced by some of enteric bacteria including *E*. *coli*. That is absorbed into the intestine, and transported by the blood to the liver, where it is converted into indoxyl sulfate, and reenters the bloodstream \[[@pone.0232461.ref016]\]. Indoxyl sulfate is known to be a uremic toxin \[[@pone.0232461.ref017]\]. When kidney function is normal, indoxyl sulfate enters the renal tubular cells and is eventually excreted from the urine \[[@pone.0232461.ref018]\]. However, indoxyl sulfate remains highly in patients with chronic kidney disease (CKD), leading to an accelerated decline of kidney function \[[@pone.0232461.ref019]\].

AST-120 (Kremezin) is an oral carbonaceous adsorbent, used to treat progressive CKD by delaying the progression of the disease, followed by the initiation of dialysis \[[@pone.0232461.ref017], [@pone.0232461.ref020]\]. In enteric sites, AST-120 adsorbs uremic toxin precursors, including indole, produced by enteric bacteria, and reduces the production of uremic toxins, such as indoxyl sulfate \[[@pone.0232461.ref021]\].

We hypothesized that AST-120 adsorbs indole produced by *E*. *coli* and then attenuates indole signaling of *E*. *coli* species, including EHEC, which in turn decreases drug tolerance and type III secretion system-associated virulence elevated by indole. In this study, we assessed the *in vitro* role of AST-120 as a potential inhibitor of indole signaling. We show evidence that AST-120 can attenuate drug tolerance and virulence induced by indole signaling.

Materials and methods {#sec002}
=====================

Bacterial strains, plasmids and culture conditions {#sec003}
--------------------------------------------------

The bacterial strains and plasmids used in this study are described in [Table 1](#pone.0232461.t001){ref-type="table"}. Bacteria were grown in LB (Luria-Bertani) medium or DMEM (Dulbecco's Modified Eagle Medium), and cell growth was monitored by absorbance at 600 nm. The pNNacrD-P \[[@pone.0232461.ref013]\], pNNgadE-P \[[@pone.0232461.ref013]\], and pNNglpT-P \[[@pone.0232461.ref022]\] are *lacZ* fusion reporter plasmids that monitor promoter activities of *acrD*, *gadE* and *glpT*, respectively. Each DNA fragment containing its promoter sequence was ligated to promoter-less *lacZ* on a pNN387 plasmid \[[@pone.0232461.ref023]\], allowing the promoter activity to be assessed according to β-galactosidase levels from LacZ expression on the plasmid. For the maintenance of plasmids, chloramphenicol was added to the growth media at a concentration of 30 μg/ml.

10.1371/journal.pone.0232461.t001

###### Strains and plasmids used in this study.

![](pone.0232461.t001){#pone.0232461.t001g}

  Strain or plasmid                                 Relevant genotype/phenotype                           Reference
  ------------------------------------------------- ----------------------------------------------------- ----------------------------
  Strains                                                                                                 
  MG1655                                            *E*. *coli* K-12; wild type; reporter strain          \[[@pone.0232461.ref024]\]
  MC4100                                            *E*. *coli* K12, lacking the endogenous *lacZ* gene   \[[@pone.0232461.ref025]\]
  MC4100ΔacrB                                       *acrB* mutant from MC4100                             \[[@pone.0232461.ref013]\]
  O157:H7 Sakai                                     Wild-type parent EHEC O157:H7 (RIMD 0509952)          \[[@pone.0232461.ref026]\]
  O157ΔtnaA                                         *tnaA* mutant from O157:H7 Sakai                      \[[@pone.0232461.ref014]\]
  Plasmids                                                                                                
  pNNacrD-P[^a^](#t001fn002){ref-type="table-fn"}   *acrD* promoter reporter; Cm^R^                       \[[@pone.0232461.ref013]\]
  pNNgadE-P[^a^](#t001fn002){ref-type="table-fn"}   *gadE* promoter reporter; Cm^R^                       \[[@pone.0232461.ref013]\]
  pNNglpT-P                                         *glpT* promoter reporter; Cm^R^                       \[[@pone.0232461.ref022]\]

Cm^R^: Chloramphenicol resistance

^a^ Formally named pNNacrD and pNNyhiE, respectively

EspB antiserum {#sec004}
--------------

EspB antiserum was produced in rabbits by Sigma-Aldrich Co. LLC (St. Louis, MO). A peptide synthesized from positions 294 to 312 of EspB was used as an antigen.

Measurement of indole in bacterial culture {#sec005}
------------------------------------------

To determine indole levels in *E*. *coli* culture, we measured the indole concentration of the culture supernatant because most of indole produced by *E*. *coli* was secreted into culture media \[[@pone.0232461.ref027]\]. Bacteria were grown in the LB medium for 24 hours, and the cell cultures were centrifuged to remove the cell pellets. Indole in the culture supernatants was extracted with ethyl acetate, then 0.7 ml of Kovac's reagent (10 g of *p*-dimethylaminobenzaldehyde, 50 ml of HCl and 150 ml of amylalcohol) was added to 0.02 mL of the ethyl acetate fraction containing indole. The indole concentration was calculated by absorbance at 540 nm according to the standard curve using commercial indole (FUJIFILM Wako Pure Chemical Industries Corp., Osaka, Japan).

Minimum inhibitory concentration (MIC) assays {#sec006}
---------------------------------------------

MIC assays were performed by a serial agar dilution method. Bacteria were grown with or without indole in LB medium to the early-stationary phase. Five microliters of 100-fold-diluted cultures (\~5,000 cells) was inoculated onto a LB agar plate containing drugs with or without indole and incubated for 16 h at 37°C. The MICs were determined as the lowest concentration at which growth was inhibited.

Survival assays {#sec007}
---------------

Bacteria were grown with or without indole and/or AST-120 in LB medium to the mid-logarithmic phase, then 5.0 x 10^7^ cells were transferred into the fresh LB medium containing either drug; 25 μg/ml aztreonam, 1.56 μg/ml fosfomycin or 75 μg/ml rhodamine 6G, and incubated with shaking. At indicated time points, aliquots of the cultures were sampled, and the number of viable cells was determined as the colony forming unit (CFU) by plating serial dilutions on LB agar. Percentage survival was calculated as the value of CFU for cells after incubated with drug relative to the value of CFU for cells prior to incubation with drug as time 0.

Promoter assays {#sec008}
---------------

Promoter activities were evaluated as β-galactosidase activities from LacZ expression on the reporter plasmids. The *E*. *coli* MC4100 strains carrying pNN-glpT-P, pNN-acrD-P or pNN-gadE-P, the LacZ reporter plasmids, were grown at 37°C in LB medium. β-Galactosidase levels from LacZ expression were determined using a Tropix Galacto-Light Plus according to the manufacturer's protocol (Thermo Fisher Scientific, Waltham, MA) as previously indicated \[[@pone.0232461.ref028]\].

Measurement of tryptophan, aztreonam, ciprofloxacin, rhodamine 6G, rifampicin, minocycline, trimethoprim, sulfamethoxazole, fosfomycin and colistin in bacteria-free aqueous solution after treatment of AST-120 {#sec009}
----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

Each compound in aqueous solution was incubated for 2 hours in the presence and absence of 30 mg AST-120. Drug concentrations except fosfomycin, colistin and amikacin were calculated by measuring absorbance at 280 nm. Concentrations of fosfomycin and colistin and amikacin were measured by a diffusion disc assay using the *E*. *coli* MG1655 reporter strain as previously indicated \[[@pone.0232461.ref015]\] because these compounds have no aromatic ring structure, therefore do not absorb the light of 280 nm wavelength.

EspB detection {#sec010}
--------------

EHEC strains were grown at 37°C with shaking to the early stationary phase in DMEM, and separated by centrifugation and filtration. Secreted proteins were precipitated from the supernatants with 10% trichloroacetic acid (TCA) and dissolved in Laemmli sample buffer (Bio-Rad Laboratories, Hercules, CA). The solution was boiled, and the proteins were separated on a 12.5% acrylamide Tris-glycine SDS/PAGE gel. The gel was electroblotted onto a polyvinylidene fluoride (PVDF) membrane (Bio-Rad Laboratories, Hercules, CA). EspB was detected with EspB antiserum with secondary anti-rabbit horseradish peroxidase-conjugated immunoglobulin G (IgG) (Sigma-Aldrich Co. LLC., St. Louis, MO) and SuperSignal West Pico Kit (Thermo Fisher Scientific, Waltham, MA). Protein bands of EspB were visualized on a LAS-4010 Luminescent image analyzer (GE Healthcare Japan, Tokyo).

Results {#sec011}
=======

AST-120 adsorbs not only indole produced by *E*. *coli*, but also tryptophan, a substrate of indole production, which decreases the level of indole in media {#sec012}
------------------------------------------------------------------------------------------------------------------------------------------------------------

To confirm the ability of AST-120 to adsorb indole, we incubated indole with AST-120 in a bacterial-free solution and then measured the level of indole in the supernatant after the removal of AST-120. *E*. *coli* strains, including EHEC produce indole in the range of 0.3--0.7 mM when grown in LB medium \[[@pone.0232461.ref027]\]. Indole is produced from tryptophan, then its production can be increased by exogenous addition of the tryptophan substrate. We found that *E*. *coli* strains, including the K-12 laboratory and EHEC strains MG1655 and O157:H7 Sakai, respectively, produced 2 mM indole when grown to the stationary phase in LB medium containing tryptophan, therefore we tested 2 mM indole to examine the effect of AST-120 in this study. More than 98% of the indole was adsorbed when incubated with at least 30 mg AST-120 ([Fig 1A](#pone.0232461.g001){ref-type="fig"}). Indole has a bicyclic structure consisting of a benzene ring fused to a pyrrole ring. Because tryptophan has the same bicyclic structure, we tested whether AST-120 also adsorbs tryptophan. Our results showed that almost all 2.5 mM tryptophan in solution was adsorbed when incubated with 30 mg AST-120 ([Fig 1B](#pone.0232461.g001){ref-type="fig"}). These findings indicate that AST-120 adsorbs both indole and tryptophan, which leads to a reduction in indole levels in *E*. *coli* culture.

![Determination of indole and tryptophan levels.\
(A) Indole concentration in supernatant from bacteria-free solution containing 2 mM indole after incubated for 2 hours with or without AST-120. (B) Tryptophan concentration in the supernatant from bacteria-free solution containing 2.5 mM tryptophan after incubated for 2 hours with or without AST-120. Data plotted are the means from three independent experiments; error bars indicate the standard deviations, \*, *P*\<0.05; \*\*, *P*\<0.01; \*\*\*, *P*\<0.001. Asterisks denote significance for values of indole or tryptophan concentration in supernatant after incubated with AST-120 relative to those after incubated without AST-120.](pone.0232461.g001){#pone.0232461.g001}

AST-120 decreases tolerance to aztreonam, fosfomycin, and rhodamine 6G induced by indole {#sec013}
----------------------------------------------------------------------------------------

Indole induces expression of several genes that encode drug efflux pumps including *acrD* and *mdtEF*, and suppresses expression of *glpT*, which encodes a glycerol-3-phosphate/fosfomycin symporter responsible for fosfomycin uptake \[[@pone.0232461.ref013], [@pone.0232461.ref015], [@pone.0232461.ref027]\]. AST-120 may minimize the effects of indole on expression of these genes, leading to an increase of drug susceptibility. To test this hypothesis, we measured promoter activities of *acrD*, *mdtEF*, and *glpT* in MC4100, an *E*. *coli* host that lacks a chromosomal *lacZ* gene when grown in the presence or absence of indole and AST-120. Because the *mdtEF* genes are transcribed with *gadE*, which is located upstream of *mdtEF*, we used the *gadE* promoter--*lacZ* reporter plasmid to assess expression of *mdtEF*. Consistent with our previous results, indole increased LacZ expression from *acrD* and *gadE* promoters while decreasing expression from the *glpT* promoter ([Fig 2A](#pone.0232461.g002){ref-type="fig"}). However, when grown in the presence of AST-120, no effect of indole on LacZ expression was observed ([Fig 2A](#pone.0232461.g002){ref-type="fig"}). *acrD* and *mdtEF* overexpression decrease susceptibility to aztreonam and rhodamine 6G, respectively while reduction of *glpT* expression decreases susceptibility to fosfomycin \[[@pone.0232461.ref015], [@pone.0232461.ref029]--[@pone.0232461.ref030]\]. We tested the susceptibilities of the MC4100 strain to aztreonam and fosfomycin when grown with or without indole and AST-120. To test the susceptibility to rhodamine 6G, we used MC4100ΔacrB as a host strain because *E*. *coli* is not susceptible to rhodamine 6G due to the AcrAB drug efflux pump, which is constitutively produced \[[@pone.0232461.ref030]\]. Consistent with previous studies, bacteria grown with indole were lower susceptible to these drugs than those grown without indole. In addition, we here showed that indole increases tolerance to these drugs. Drug tolerance is characterized by a slower killing even at high concentrations of the drug while MIC of the drug is not changed in contrast to drug resistance \[[@pone.0232461.ref003]\]. Indole addition did not increase MICs of aztreonam, fosfomycin and rodamine 6G in cultures of the MC4100 and MC41000ΔacrB strains (data not shown). On the other hand, compared to the strains grown without indole, the strains grown with indole were slowly killed during exposure of these drugs, suggesting that indole increases tolerance, but not resistance, ([Fig 3A--3C](#pone.0232461.g003){ref-type="fig"}). When AST-120 was present, the strains grown with indole were similarly killed to those grown without indole ([Fig 3A--3C](#pone.0232461.g003){ref-type="fig"}). We also note that AST-120 addition does not affect innate tolerance to aztreonam and fosfomycin because these killing curves for cells grown without indole in the presence of AST-120 were similar to those in the absence of AST-120. On the other hand, AST-120 addition moderately prolonged bacterial survival for cells grown without indole during exposure of rhodamine 6G although we do not know the reason. As a consequence, AST-120 suppresses the effect of indole on induction of AcrD, MdtEF, and GlpT-associated drug tolerance.

![Measurement of promoter activities.\
(A) β-Galactosidase activities of MC4100 containing pNNacrD-P, pNNgadE-P or pNNglpT-P, the *lacZ* reporter plasmid grown with or without indole and/or AST-120. (B) β-Galactosidase activities correspond to *acrD* promoter activities in MC4100ΔtnaAB grown with or without indole before or after incubated with or without AST-120. β-Galactosidase activities represent values of chemiluminescence normalized by OD~600~ correspond to the LacZ expression. Data plotted are the means from three independent experiments; error bars indicate the standard deviations, \*\*, *P*\<0.01; \*\*\*, *P*\<0.001. Asterisks denote significance for values of promoter activities in *E*. *coli* host cultured with indole relative to those in *E*. *coli* host cultured without indole.](pone.0232461.g002){#pone.0232461.g002}

![Killing curves of MC4100 (for aztreonam and fosfomycin) and MC4100ΔacrB (for rhodamine 6G).\
Bacteria were grown with or without indole and/or 30 mg AST-120, and thereafter incubated with 25 μg/ml aztreonam (A), 1.56 μg/ml fosfomycin (B) or 75 μg/ml rhodamine 6G (C). The survival rates at indicated time points were described as percent of CFUs for strains after incubation with the drug relative to those before incubation with the drug. Data plotted are the means and error bars indicate the ranges.](pone.0232461.g003){#pone.0232461.g003}

We also tested whether AST-120 terminates the effect of indole on induction of gene expression. Two sets of bacteria were grown with indole to the mid-logarithmic phase, at which point AST-120 was added to the first set of bacterial cultures, and its culture was continued to the stationary phase whereas the other set of bacterial cultures was similarly continued but without added AST-120. For this experiment, we chose the *acrD* promoter. We found that the level of LacZ expression in bacteria when AST-120 was added was lower than that of bacteria to which AST-120 was not added ([Fig 2B](#pone.0232461.g002){ref-type="fig"}).

AST-120 decreases EspB level elevated by indole {#sec014}
-----------------------------------------------

EspB, which is secreted via the type III secretion system by EHEC, and this protein contributes to pathogenicity in host epithelial cells \[[@pone.0232461.ref031]\]. Previously, we found that indole increases secretion of this protein \[[@pone.0232461.ref014]\]. In this study, we tested the effect of AST-120 addition on EspB secretion. We grew wild-type parent EHEC and the *tnaA* mutant in Dulbecco's Modified Eagle Medium (DMEM) containing tryptophan or indole. In the preliminary experiment, we found that the wild-type parent produces 0.3 mM of indole in DMEM when tryptophan is added. We therefore used this concentration of indole for the EspB experiment ([Fig 4A](#pone.0232461.g004){ref-type="fig"}). We found that the addition of AST-120 reduced EspB levels in the wild-type parent ([Fig 4B](#pone.0232461.g004){ref-type="fig"}). As in our previous study, EspB levels of the *tnaA* mutant when grown with tryptophan were lower than those of the wild-type parent because the *tnaA* mutant does not produce indole, and it was elevated when grown with exogenous indole. AST-120 addition decreased EspB levels in culture. Thus, AST-120 reduces indole level, then the wild-type parent grown in the presence of AST-120 behaves as the *tnaA* mutant.

![Determination of indole and EspB levels in supernatant of EHEC O157.\
(A) Indole concentration in culture supernatant of the wild-type parent EHEC O157 grown in DMEM containing 0.5 mM tryptophan with or without AST-120. Data plotted are the means from three independent experiments; error bars indicate the standard deviations, \*\*, *P*\<0.01; \*\*\*, *P*\<0.001. Asterisks denote significance for values of indole concentration in supernatant after incubated with AST-120 relative to those after incubated without AST-120. (B) The wild-type parent and the *tnaA* mutant were grown in DMEM containing 0.5 mM tryptophan or 0.3 mM indole with or without AST-120. Secreted proteins including EspB were separated by SDS/PAGE, and EspB was visualized by western blotting with EspB antiserum.](pone.0232461.g004){#pone.0232461.g004}

AST-120 does not adsorb fosfomycin, rifampicin, colistin, or aminoglycosides, such as amikacin {#sec015}
----------------------------------------------------------------------------------------------

AST-120 may adsorb not only indole and tryptophan but also some classes of antimicrobial agents. This property may limit the effectiveness of a combination therapy that uses AST-120 and a common antimicrobial agent. We tested the capability of AST-120 to adsorb antimicrobial agents that are generally active in *E*. *coli* species, including aztreonam and fosfomycin, to which tolerance is induced by indole. AST-120 adsorbed aztreonam, ciprofloxacin, minocycline, trimethoprim, and sulfamethoxazole, but not fosfomycin, rifampicin, colistin, or amikacin. Fosfomycin, rifampicin, colistin, and aminoglycosides, such as amikacin, are therefore still useful, even when AST-120 is present ([Fig 5](#pone.0232461.g005){ref-type="fig"}). In addition, AST-120 did not adsorb rhodamine 6G although it is not generally used for the treatment of bacterial infectious diseases.

![Drug adsorption by AST-120.\
Each drug in aqueous solution was incubated for 2 hours with or without AST-120. The *y* axis on the graph shows percent of drug concentration after incubation with AST-120 relative to drug concentration after incubation without AST-120. Data are the means of two biological replicates; error bars indicate the ranges.](pone.0232461.g005){#pone.0232461.g005}

Discussion {#sec016}
==========

AST-120 is used to treat progressive CKD by inhibiting the production of indoxyl sulfate, a uremic toxin derived from indole that is produced by some kinds of enteric bacteria, such as *E*. *coli* \[[@pone.0232461.ref021]\]. When kidneys function normally, the renal tubular cells remove indoxyl sulfate from the blood and eventually drain it with the urine \[[@pone.0232461.ref017]\]. However, in CKD patients, indoxyl-sulfate accumulates in the kidney and blood, where it generates reactive oxygen species (ROS), and induces oxidative cell damage \[[@pone.0232461.ref032]\]. Therefore, indoxyl sulfate not only accelerates kidney function decline but also damages vascular endothelial cells. Animal studies have shown that indoxyl sulfate disturbs the cardiovascular system, whereas administration of AST-120 alleviates it \[[@pone.0232461.ref033]--[@pone.0232461.ref034]\]. In this study, we propose that AST-120 plays another beneficial role against enteric infectious diseases caused by pathogenic *E*. *coli*, including EHEC, although this role may be limited because AST-120 adsorbs some antimicrobial agents. We provided evidence that AST-120 suppresses indole signaling of *E*. *coli* by adsorbing both indole and tryptophan (a substrate for indole production) and decreasing tolerance to particular antimicrobial agents, including aztreonam, fosfomycin, rhodamine 6G, and type III secretion proteins.

When bacteria communicate with other bacteria, they produce diffusible signaling molecules, such as autoinducers, and alter expression profiles in subsets of genes \[[@pone.0232461.ref005]\]. This activity is termed "bacterial cell-to-cell communication." There is increasing evidence that this activity is closely associated with drug resistance and pathogenicity and is therefore a possible efficient target for the treatment of refractory infectious diseases caused by pathogens resistant to traditional antibiotics. Gram-negative bacteria commonly use acyl-homoserine lactones (AHLs) as signaling molecules \[[@pone.0232461.ref008]\]. In addition to AHLs, some species also use autoinducer-2 \[[@pone.0232461.ref007]\]. *E*. *coli* uses indole instead of AHLs. It is produced not only by *E*. *coli* but also by other enteric bacteria, such as *Proteus* spp. \[[@pone.0232461.ref035]\]. Indole is synthesized from tryptophan, an essential amino acid contained in food, and some share of it is eventually converted into indoxyl sulfate \[[@pone.0232461.ref016]\]. However, a high level of indole can still accumulate at enteric sites \[[@pone.0232461.ref036]\]. Therefore, indole may increase resistance to some drugs and *E*. *coli* at enteric sites. AST-120 is expected to be able to remove indole. Indole also increases drug resistance of *Salmonella enterica via* induction of AcrAB, a drug efflux pump, and biofilm formation of *Vibrio cholera* \[[@pone.0232461.ref037]--[@pone.0232461.ref038]\]. AST-120 administration may therefore contribute to therapies for these enteric infections. On the other hand, indole suppresses virulence of *P*. *aeruginosa* and *Staphylococcus aureus*, increases drug susceptibility in *Lysobacter* species and inhibits *P*. *aeruginosa* persister cell resuscitation \[[@pone.0232461.ref011]--[@pone.0232461.ref012], [@pone.0232461.ref039]--[@pone.0232461.ref040]\]. Therefore, we have to note that AST-120 may exhibit detrimental aspects in some of cases. However, we believe that AST-120 still has a merit for treatment of *E*. *coli* infections including EHEC.

Many studies report on the inhibition of bacterial signaling, and studies on AHL inhibitors are well known \[[@pone.0232461.ref006]\]. Although many cases involving antagonists target the receptors, some molecules inactivate signaling at the extracellular space without being incorporated into the bacterial cells. Cyclodextrins, for example, can capture AHLs in a matrix \[[@pone.0232461.ref041]\]. AST-120 inhibits indole signaling, and it works in extracellular spaces in a manner similar to that of cyclodextrins. These compounds may not be affected by membrane permeability and the presence of efflux pump. Some species of soil bacteria oxidize or degrade indole \[[@pone.0232461.ref042]--[@pone.0232461.ref043]\]. The enzymes catalyzing these reactions are also considered potential indole-signaling inhibitors. Compared with these degradation and modification enzymes, AST-120 is relatively small and stable.

However, tryptophan metabolites, including indole, also have beneficial aspects for host cells, therefore AST-120 may interfere with their beneficial actions. Studies in mice showed that low levels of indole alleviate liver and colonic inflammation in inflammatory bowel disease (IBD) \[[@pone.0232461.ref044]--[@pone.0232461.ref045]\]. Several *Clostridium* species, such as *C*. *sporogenes*, produce indole propionic acid (IPA) from tryptophan \[[@pone.0232461.ref046]\]. IPA promotes intestinal barrier function via activation of pregnane X receptor (PXR) while helping protect host cells from oxidative damage by scavenging hydroxyl radicals \[[@pone.0232461.ref047]--[@pone.0232461.ref048]\]. Tryptamine produced by *C*. *sporogenes* and *Ruminococcus gnavus* acts on enterochromaffin cells, inducing the release of 5-hydroxytryptamin, (5-HT) which stimulates gastrointestinal motility \[[@pone.0232461.ref049]--[@pone.0232461.ref050]\]. Treatment with indole-3-carboxaldehyde (ICA) limits gut epithelial damage, reduces transepithelial bacterial translocation, and decreases inflammatory cytokine production \[[@pone.0232461.ref051]\]. Therefore, to enhance the potential efficacy of AST-120 therapy, establishing a method that minimizes interference of the beneficial effects caused by tryptophan metabolites may be important.

We note that AST-120 adsorbs some kinds of antimicrobial agents, such as aztreonam and ciprofloxacin which are commonly used to treat of *E*. *coli* infections. However, fosfomycin, colistin, rifampicin, and aminoglycosides are still not adsorbed by AST-120. Although fosfomycin is an old-generated antibiotic, it recently has attracted attention as a "last resort drug" to treat multidrug resistant (MDR) pathogens \[[@pone.0232461.ref052]\]. Increasingly, pathogenic *E*. *coli* clones that are resistant to quinolones and β-lactams, including carbapenem, have becomes a critical issue in clinical settings. Therefore, AST-120 may offer a potential benefit by helping fosfomycin therapy treat *E*. *coli* infections.

10.1371/journal.pone.0232461.r001
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**Comments to the Author**

1\. Is the manuscript technically sound, and do the data support the conclusions?

The manuscript must describe a technically sound piece of scientific research with data that supports the conclusions. Experiments must have been conducted rigorously, with appropriate controls, replication, and sample sizes. The conclusions must be drawn appropriately based on the data presented.

Reviewer \#1: Yes

Reviewer \#2: Partly

\*\*\*\*\*\*\*\*\*\*

2\. Has the statistical analysis been performed appropriately and rigorously?

Reviewer \#1: Yes

Reviewer \#2: N/A

\*\*\*\*\*\*\*\*\*\*

3\. Have the authors made all data underlying the findings in their manuscript fully available?

The [PLOS Data policy](http://www.plosone.org/static/policies.action#sharing) requires authors to make all data underlying the findings described in their manuscript fully available without restriction, with rare exception (please refer to the Data Availability Statement in the manuscript PDF file). The data should be provided as part of the manuscript or its supporting information, or deposited to a public repository. For example, in addition to summary statistics, the data points behind means, medians and variance measures should be available. If there are restrictions on publicly sharing data---e.g. participant privacy or use of data from a third party---those must be specified.

Reviewer \#1: Yes

Reviewer \#2: No

\*\*\*\*\*\*\*\*\*\*

4\. Is the manuscript presented in an intelligible fashion and written in standard English?

PLOS ONE does not copyedit accepted manuscripts, so the language in submitted articles must be clear, correct, and unambiguous. Any typographical or grammatical errors should be corrected at revision, so please note any specific errors here.

Reviewer \#1: Yes

Reviewer \#2: Yes

\*\*\*\*\*\*\*\*\*\*

5\. Review Comments to the Author

Please use the space provided to explain your answers to the questions above. You may also include additional comments for the author, including concerns about dual publication, research ethics, or publication ethics. (Please upload your review as an attachment if it exceeds 20,000 characters)

Reviewer \#1: This manuscript titled"In vitro Activity of AST-120 That Suppresses Indole Signaling in Escherichia coli, Which Attenuates Drug Tolerance and Virulence" describes a series of conclusions, and the experimental results are very detailed. However, the current status cannot be published yet, and the following modifications need to be completed before publication.

1\. The introduction of indoles is not comprehensive enough, and there is a lack of multiple references, such as the recent studies by Thomas K Wood. Several new developments regarding Lysobacter were also not mentioned. These need to be added.

2\. In Figure1, the significant change in statistics is only shown as P\<0.01 and is only represented by single asterisk. The author needs to use one, two, and three asterisks for different P values.

3\. In figure 1, the effect of 10mg ast-120 is obvious, what about 1mg or 5mg? This data needs to be shown in the diagram. This series of data needs to be improved.

4\. English writing needs polishing.

5\. There are many studies on the regulation of drug resistance by indoles. Previous studies have shown that indoles increase drug resistance in some bacteria and inhibit drug resistance in others. Are these background studies relevant to this study? Is there any inspiration? Need to be reflected in the discussion.

Reviewer \#2: The manuscript describes a novel observation that AST-120 (Kremezin), used clinically for chronic kidney disease, is capable of adsorbing indole (in addition to a range of other molecules). One would naturally conclude that the addition of AST-120 to a bacterial culture will interfere with most indole-related signalling pathways, not because AST-120 is interfering in these pathways but simply because indole is absent/decreased. The authors demonstrate this expected outcome in a range of assays (antibiotic tolerance, regulation of genes encoding efflux pumps and fosfomycin permease & secretion of EspB protein). However, the authors claim that AST-120 interferes in these pathways. This claim is unsubstantiated as AST-120 has no effect on these pathways if indole is not present, as shown by their results. Therefore, these assays simply confirm the initial observation of AST-120 adsorbing indole without providing any added significance.

Abstract:

Lines 40-42: The results suggest only that AST-120 can adsorb a range of compounds. There is no data to support that a combination therapy of AST-120 with quinolones or B-lactams will lead to a better clinical outcome, hence the statement is unjustified.

Introduction:

Lines 73: The authors should explain the difference between resistance and tolerance for the benefit of the lay audience, I suggest referring to Nature Reviews Microbiology 14, 320 (2016) & mBio 10, e02095-19 (2019). Tolerant and persistent bacteria can survive antibiotic treatments without having acquired a resistance phenotype. In contrast to resistance, which enables bacteria to grow in a concentration of a drug that would otherwise prevent growth, tolerance is only a transient ability of bacteria to survive under otherwise bactericidal treatments.

Lines 75-81: The authors describe indole as a detrimental molecule on the host. This is inaccurate as indole has been reported to have both positive and negative effects (For example, see FEMS Nicrobiol Rev 34, 426-44 (2010) & Trends Microbiol 23, 707-718 (2015)).

Materials and Methods:

Lines 123-131: "Drug susceptibility assays" is described vaguely (what is the starting cfu/ml before treatment? Why incubation with no shaking? Why 60 min incubation for the antibiotics but 30 min for rhodamine G?). Also, the choice of the technique is odd.

As a starting point, MICs should be assayed for all tested antibiotics (and Rhodamine G) before and after the addition of AST-120 to confirm that we are looking at an increased tolerance not increased resistance. In contrast with resistance, tolerance do not lead to an increase in the MIC compared with susceptible bacteria (See Nature Reviews Microbiology 17, 441-448 (2019)).

Next, tolerance is characterised by a slower killing even at high concentrations of the drug, and that is assayed by either MDK99 (the minimum duration of treatment that kills 99% of the bacterial population) (See Nat Rev Microbiol 14:320--330 (2016)) or TDtest (see Sci Rep 7, 41284 (2017).

The authors need to comment on the suitability of their chosen method, considering that it is not how tolerance is usually assayed, unless the authors do not mean actually "tolerance"!

Lines 146-147: What is the basis of using OD280nm to calculate the concentrations of antibiotics? Why is it changes to 525nm for Rhodamine G?

Lines 148-149: The disk diffusion assays will be influenced by the presence of AST-120. I am wondering if the authors have tested whether AST-120 alone has any inhibitory effect on MG1655?

Results:

Line 170: What does "authentic" indole means?

Lines 172-175: The authors justify using 2 mM indole by describing that cultures of stationary phase E. coli in LB contain around 2 mM indole. This is buzzling as the concentration is known to be in the range of 0.3 -- 0.7 mM, which is nowhere near 2 mM. See for example

\- Di Martino, P., et al., Indole can act as extracellular signal to regulate biofilm formation of Escherichia coli and other indole-producing bacteria. Canadian journal of Microbilogy, 2003. 49(7): p. 443-449.

\- Domka, J., J. Lee, and T.K. Wood, YliH (BssR) and YceP (BssS) Regulate Escherichia coli K-12 Biofilm Formation by Influencing Cell Signalling. Appl. Environ. Microbial., 2006. 72(4): p. 2449-2459.

\- Hirakawa, H., et al., Secreted indole serves as a signal for expression of type III secretion system translators in enterohaemorrhagic Escherichia coli O157 : H7. Microbiology, 2009. 155(2): p. 541-550.

The authors need to comment on this contradiction.

Lines 177-178 & Fig 1B: The authors have shown than AST-120 adsorbs tryptophan as well as indole. Thus, when adding AST-120 to a tryptophan containing media, it is not possible to determine whether the reduction of indole is due to AST-120 adsorption of indole or tryptophan? This experiment is rather messy with no clear conclusion.

Lines 214-215: The authors conclude that "AST-120 suppresses AcrD-, MdtEF-, and GlpT-associated drug tolerance induced by indole". This is not what the results show. The results simply show that AST-120 adsorbs indole (almost completely). This means that indole effects will be abolished by the addition of AST-120. Not because AST-120 interferes in the indole effects but simply because indole is not there anymore. In other words, AST-120 does NOT suppress AcrD-, MdtEF-, and GlpT-associated drug tolerance, but simply adsorbs indole so these effects are not there anymore.

Lines 216-222 & Fig 2B: Similar to my previous point, the addition of AST-120 did not affect the level of LacZ expression directly but simply adsorbed indole, thereby the expression of LacZ was decreased.

Lines 232-233: (Fig. 3A & B) should be (Fig. 4A & B).

Lines 237-238: Again, AST-120 does NOT decrease EspB levels as claimed by the authors. AST-120 adsorbs indole thus the WT strains behaves exactly as a ΔtnaA strain.
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2\. Is the manuscript technically sound, and do the data support the conclusions?

The manuscript must describe a technically sound piece of scientific research with data that supports the conclusions. Experiments must have been conducted rigorously, with appropriate controls, replication, and sample sizes. The conclusions must be drawn appropriately based on the data presented.
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